Ticagrelor/Strong CYP3A4 Inducers
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your medicine may speed up how quickly your body processes ticagrelor.
What might happen:
The amount of ticagrelor in your blood may decrease and it may not work as well.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together or if you have used carbamazepine, dexamethasone, phenobarbital, phenytoin, primidone or rifampin in the previous two weeks. Your doctor may want to change your medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
References:
1.Brilique (ticagrelor) UK summary of product characteristics. AstraZeneca UK Limited October 24, 2012.
2.Brilinta (ticagrelor) US prescribing information. AstraZeneca LP March, 2013.
3.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
